53BP1 is a chromatin-binding protein that regulates the repair of DNA double-strand breaks by suppressing the nucleolytic resection of DNA termini 1,2 . This function of 53BP1 requires interactions with PTIP 3 and RIF1 4-9 , the latter of which recruits REV7 (also known as MAD2L2) to break sites 10,11 . How 53BP1-pathway proteins shield DNA ends is currently unknown, but there are two models that provide the best potential explanation of their action. In one model the 53BP1 complex strengthens the nucleosomal barrier to end-resection nucleases 12,13 , and in the other 53BP1 recruits effector proteins with end-protection activity. Here we identify a 53BP1 effector complex, shieldin, that includes C20orf196 (also known as SHLD1), FAM35A (SHLD2), CTC-534A2.2 (SHLD3) and REV7. Shieldin localizes to double-strand-break sites in a 53BP1-and RIF1-dependent manner, and its SHLD2 subunit binds to singlestranded DNA via OB-fold domains that are analogous to those of RPA1 and POT1. Loss of shieldin impairs non-homologous endjoining, leads to defective immunoglobulin class switching and causes hyper-resection. Mutations in genes that encode shieldin subunits also cause resistance to poly(ADP-ribose) polymerase inhibition in BRCA1-deficient cells and tumours, owing to restoration of homologous recombination. Finally, we show that binding of single-stranded DNA by SHLD2 is critical for shieldin function, consistent with a model in which shieldin protects DNA ends to mediate 53BP1-dependent DNA repair.
and RNF168) or downstream (RIF1) of 53BP1 were hits in the RPE1 BRCA1 KO screen (Supplementary Table 1 ). The presence of 53BP1 and 53BP1-pathway proteins suggested that these screens could reveal hitherto uncharacterized 53BP1 effectors.
In competitive growth assays ( Fig. 1b ), sgRNAs targeting 53BP1 (also known as TP53BP1) led to the outgrowth of BRCA1 KO cells in the presence of olaparib ( Fig. 1c ; genotyping information in Supplementary  Table 2 ). Similarly, sgRNAs targeting C20orf196, ATMIN and SCAF1 led to resistance to PARPi ( Fig. 1c and Extended Data Fig. 1b ). In parallel studies, transfection of CRISPR RNAs (crRNAs) and trans-activating crRNAs (tracrRNAs) that target C20orf196, 53BP1 or PARP1 caused talazoparib resistance in SUM149PT cells ( Fig. 1d and Extended Data Fig. 1c ). Because C20orf196 was identified as a hit in all three screens and validated in independent assays, we sought to determine its role in DNA repair.
C20orf196 is an uncharacterized protein comprising 205 amino acid residues ( Fig. 1e ), previously identified as a candidate REV7interacting protein 19 . We used immunoprecipitation coupled to mass spectrometry (IP-MS) to expand the interaction network surrounding the REV7-interacting proteins ( Fig. 1f and Supplementary Table 3 ). One protein, FAM35A, was enriched in both C20orf196 and REV7 immunoprecipitation samples ( Fig. 1f ). FAM35A was notable owing to the presence of three predicted OB-fold domains (OBA, OBB and OBC; Fig. 1e ), reminiscent of those in the single-stranded DNA (ssDNA)-binding proteins RPA1 20 and POT1 21 . IP-MS experiments with FAM35A recovered CTC-534A2.2, also identified in the REV7 IP-MS ( Fig. 1f and Supplementary Table 3 ). CTC-534A2.2 is a protein encoded by an alternative mRNA emanating from the TRAPPC13 locus ( Fig. 1e and Extended Data Fig. 1d ). sgRNAs against CTC-534A2.2 were not present in either of our first-generation sgRNA libraries. IP-MS with CTC-534A2.2 recovered C20orf196, FAM35A and REV7 ( Fig. 1f and Supplementary Table 3 ), which suggests that these proteins form a single protein complex-this was confirmed by sequential affinity purification of epitope-tagged C20orf196, CTC-534A2.2, FAM35A and REV7 (Fig. 1g) .
FAM35A, C20orf196 and CTC-534A2.2 were identified in a fourth CRISPR-Cas9 screen using a second-generation sgRNA library, TKOv2. This screen sought to identify genes that promote resistance to ionizing radiation in RPE1 cells (Extended Data Fig. 1e ). Seventyfive genes scored at a false discovery rate (FDR) < 1% and this gene set was found to be highly enriched in genes that encode nonhomologous end-joining (NHEJ) factors by Gene Ontology enrichment (P = 1.11 × 10 −11 , Fisher's exact test with multiple correction;
Letter reSeArCH Fig. 2a and Supplementary Table 4 ). RIF1, FAM35A, C20orf196, CTC-534A2.2, 53BP1 and REV7 were all hits at FDR < 1% ( Fig. 2a) . These data suggest that the complex formed by C20orf196, FAM35A, REV7 and CTC-534A2.2 promotes the repair of double-strand breaks (DSBs) by NHEJ. For reasons that will become apparent, we named this complex shieldin and renamed C20orf196, FAM35A and CTC-534A2.2 as SHLD1, SHLD2 and SHLD3, respectively. Independent sgRNAs targeting SHLD2 or SHLD3 caused sensitivity to the clastogen etoposide in competitive growth assays (Extended Data Fig. 1f ) and caused resistance to olaparib in RPE1 BRCA1 KO cells, consistent with SHLD2 and SHLD3 acting with REV7 and SHLD1 ( Fig. 2b and Extended Data Fig. 1g ). Clonal knockouts of SHLD1 or SHLD2 led to olaparib resistance in BRCA1 KO cells, and SHLD2 KO resulted in a phenotype that approached that of 53BP1 loss (Fig. 2c) . Similar results were obtained with 11 independent clonal knockouts of SHLD1 in SUM149PT cells exposed to talazoparib (Extended Data Fig. 1h ). Furthermore, expressing GFP-SHLD2 in double knockout BRCA1 KO SHLD2 KO Data represent mean fraction of GFP-positive cells ± s.e.m., normalized to day 0 (n = 3, independent transductions). d, Resistance to PARPi caused by mutation of C20orf196. SUM149PT cells transfected with indicated crRNAs were treated with 50 nM talazoparib for 14 d. Relative growth was normalized to a non-targeting crRNA (Ctrl). Bars represent mean ± s.d. of multiple crRNAs per gene (shown is a representative plot of 2 biologically independent experiments). e, Domain architecture of shieldin subunits. SHLD3 contains a REV7-binding PXXXPP motif 28 . f, Protein interaction network surrounding REV7, C20orf196, FAM35A and CTC-534A2.2. Solid and dashed arrows represent interactions at an FDR of ≤ 1% and ≤ 5%, respectively. g, Sequential affinity purifications from 293T cell lysates expressing the indicated proteins. Bound proteins were immunoblotted with the indicated antibodies (n = 2 independent experiments). WCE, whole-cell extract. 
Fig. 2 | Shieldin loss promotes
PARPi resistance in cell and tumour models of BRCA1-deficiency. a, CRISPR dropout screen results in RPE1 wild-type cells exposed to ionizing radiation. Gene-level normZ scores < 0 are shown. b, Competitive growth assays using olaparib (16 nM) in RPE1 BRCA1 KO cells. Data are presented as mean ± s.d., normalized to day 0 (n = 3, independent transductions). c, Clonogenic survival in response to 16 nM olaparib. Representative images are shown (left) and quantified (right). Bars represent mean ± s.d. (n = 9: RPE1 wild type and BRCA1 KO SHLD1 KO ; n = 3: BRCA1 KO SHLD2 KO , n = 4: BRCA1 KO 53BP1 KO ; biologically independent experiments). d, Quantification of cells with ≥ 5 RAD51 foci ± 10 Gy ionizing radiation (6 h recovery). Biologically independent experiments are shown and the bars represent the mean ± s.d. From left to right, the number of replicates was n = 3 (for both conditions in left panel); n = 3, 4, 3, 4, 3 and 3 (for conditions in middle panel, left to right); and n = 4, 6, 6, 6, 6, 6, 6 and 6 (for conditions in right panel, left to right). e, Assessment of gene conversion by traffic light reporter assay. Biologically independent experiments are shown and the bars represent the mean ± s.d. (n = 3 for wild type and 53BP1 KO ; n = 4 for SHLD1 KO , SHLD2 KO and REV7 KO ). f, Kaplan-Meier curve showing tumour-specific survival of mice transplanted with KB1P4 tumour organoids ± olaparib treatment for 80 d (n = 8 per treatment; editing efficiencies found in Supplementary Table 2) . P values were calculated using a log-rank test (Mantel-Cox). IR, ionizing radiation; KO, knock out; WT, wild type. Fig. 1i ). Resistance to PARPi in shieldin-deficient BRCA1 KO cells is due to restoration of homologous recombination, as measured both by RAD51 focus formation induced by ionizing radiation and by a reporter for gene conversion (the traffic light reporter assay 22 ) ( Fig. 2d , e and Extended Data Fig. 2a-d ).
Next, we tested whether loss of shieldin causes resistance to PARPi in the KB1P mouse mammary tumour model that is deficient in Brca1 and Trp53, which encodes p53 (ref. 23 ). sgRNAs targeting Shld1 and Shld2 led to resistance to PARPi in KB1P-G3 mammary tumour cells and in Brca1 −/− Trp53 −/− mouse embryonic stem cells (Extended Data Fig. 3a , c). This resistance was also associated with restoration of homologous recombination (Extended Data Fig. 3b ). Furthermore, transduction of Shld1-and Shld2-targeting sgRNAs suppressed the cell lethality associated with Brca1 loss in p53-proficient mouse embryonic stem cells (Extended Data Fig. 3d ). We transduced the same sgRNAs into KB1P4 mammary tumour organoids (Supplementary Table 2 ) and implanted them into the fat pads of mice. Olaparib treatment was initiated when tumours reached sizes of 50-100 mm 3 , and was continued for 80 days. Although all untreated mice succumbed to excessive tumour burden within 20 days, the control group responded to olaparib for the duration of the treatment (Fig. 2f ). However, mice implanted with Shld1and Shld2-mutated tumours exhibited a partial response to olaparib, with mice succumbing by day 60 (Fig. 2f ). We conclude that shieldin loss causes resistance to PARPi in both human and mouse BRCA1deficient tumour cells by reactivating homologous recombination.
As expected of a complex with a direct role in DSB repair, shieldin accumulates at DSB sites in a 53BP1-and RIF1-dependent manner ( Fig. 3a-f and Extended Data Fig. 4a-d ). Loss of shieldin components did not impair formation of 53BP1 or RIF1 foci induced by ionizing radiation, indicating that shieldin acts downstream of 53BP1-RIF1 (Extended Data Fig. 4e , f). Consistent with this possibility, we observed genetic epistasis between 53BP1 and the shieldin genes using the RAD51 focus-formation assay in RPE1 BRCA1 KO cells (Extended Data Fig. 5a ). We also observed that SHLD1 and 53BP1 were epistatic in terms of modulating talazoparib resistance in SUM149PT cells (Extended Data Fig. 5b ).
Analyses of the dependencies within the shieldin complex indicate that SHLD3 is the most apical component followed by REV7, SHLD2 and then SHLD1 ( Fig. 3c -e, Extended Data Figs. 4a-d, 6, 7c-e and Supplementary Note 1 for mapping details). Indeed, SHLD3 interacts with RIF1, which suggests that SHLD3 recruits shieldin to chromatinbound 53BP1-RIF1 ( Fig. 3g and Extended Data Fig. 7f ). Further mapping studies suggest that shieldin consists of a DSB-recruitment module composed of SHLD3-REV7 that binds to the N terminus of SHLD2 (residues 1-50; Extended Data Figs. 6, 7a-c), and a presumptive DNA-binding module (SHLD2-SHLD1) that features the OB-fold domains at the SHLD2 C terminus (hereafter SHLD2-C, residues 421-904; Extended Data Fig. 7a ).
To assess the role of shieldin in NHEJ, we first analysed class switch recombination in CH12F3-2 cells 24 . Mutation of each of the shieldin subunits compromised class switch recombination, with Shld1-edited cells having a reproducibly milder phenotype ( Fig. 3h and Extended Data Fig. 8a -c). Shld2 KO was epistatic with both 53bp1 KO and Shld1 KO mutations, consistent with them acting in the same genetic pathway (Extended Data Fig. 8b , c). The expression of AID-which initiates class switch recombination-was not altered in shieldin mutants, consistent with NHEJ deficiency (Extended Data Fig. 8d ). Supporting this possibility, SHLD1 and SHLD2 mutations impaired random plasmid integration-which occurs largely through NHEJ 25 -to an extent similar to that of 53BP1-deficient cells (Extended Data Fig. 8e, f) . (siRIF1), REV7 (siREV7), SHLD1 (siSHLD1), SHLD2 (siSHLD2) and SHLD3 (siSHLD3), respectively. f, mCherry-LacR-FokI colocalization with GFP-SHLD2, the N terminus of SHLD2 (SHLD2-N), and SHLD2-C. Mean normalized focus intensity is shown with a total of 52 (SHLD2 and SHLD2-N) or 53 (SHLD2-C) cells counted (n = 2, biologically independent experiments). g, RIF1 co-immunoprecipitation with V5-SHLD3 (representative of two independent experiments). h, Class switch recombination analysis of CH12F3-2 cells following stimulation. Data are mean ± s.d. (n = 3 biologically independent replicates, clone number of the knockout cell lines is indicated by the number following the gene name). i, Irradiated (25 Gy) CH12F3-2 clones were immunoblotted for RPA32 phosphorylation (pRPA32, phosphorylated at Ser4 and Ser8) (representative of three biological replicates, clone number of the knockout cell lines is indicated by the number following the gene name).
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The loss of each shieldin subunit led to ionizing-radiation-induced RPA32 Ser4/Ser8 phosphorylation, which is a surrogate marker of end-resection 20 , suggesting that shieldin protects DNA ends ( Fig. 3i and Extended Data Fig. 8g ). Supporting this hypothesis, the restoration of homologous recombination in shieldin-defective KB1P-G3 cells was dependent on ATM activity (Extended Data Fig. 3a, b ), which promotes DNA end-resection in the absence of 53BP1 16 or REV7 10 . An accompanying paper 26 shows that Shld2-mutated cells have increased end-resection at dysfunctional telomeres. Shieldin therefore antagonizes end-resection.
We surmised that if shieldin is a downstream effector of 53BP1, artificially targeting shieldin to DSB sites should rescue phenotypes associated with 53BP1 loss. To do this, we fused SHLD2 to the RNF8 forkhead-associated (FHA) domain, which is recruited to damaged chromatin independently of 53BP1 ( Fig. 4a ). We found that the FHAdependent targeting of SHLD2 to DSB sites suppressed RAD51 focus formation induced by ionizing radiation in BRCA1 KO 53BP1 KO cells ( Fig. 4b and Extended Data Fig. 9a ). These results suggest that SHLD2 mediates 53BP1-dependent DNA repair.
We observed that the FHA-SHLD2-C protein, which contains the OB-fold domains, potently suppressed RAD51 recruitment to DSB sites in BRCA1 KO 53BP1 KO cells ( Fig. 4b and Extended Data Fig. 9a ). This result suggested that DNA binding might underpin the effector function of the SHLD2 C terminus. To test for DNA binding activity, we affinity-purified SHLD2-C in the presence or absence of SHLD1 (Extended Data Fig. 9b ). We observed SHLD2-C binding to a radio-labelled ssDNA probe by electrophoretic mobility shift assays (EMSA), and competition with unlabelled oligonucleotides revealed that SHLD2-C preferentially binds to ssDNA over double-stranded DNA (Fig. 4c ). Although SHLD1 is not essential for the DNAbinding activity of SHLD2-C, its presence increased the amount of SHLD2-C purified, and the retarded complex displayed a difference in mobility consistent with the SHLD2-C-SHLD1 complex binding to ssDNA (Fig. 4d , lane 2 versus 5). We estimate the binding affinity of the SHLD2-C-ssDNA interaction to be about 10 nM ( Fig. 4e and Extended Data Fig. 9c ). We conclude that SHLD2 possesses ssDNA-binding activity.
To explore whether ssDNA binding is involved in shieldin function, we generated four mutant versions (named m1-m4) of the SHLD2 OB folds by modelling the SHLD2 C terminus on an RPA1 structure 27 (RCSB Protein Data Bank code: 4GNX; Extended Data Fig. 9d ). We also employed a splice variant of SHLD2 that disrupts OBB, which we refer to as SHLD2(S). We found that the SHLD2 m1 and SHLD2(S) mutants-either in the context of full-length SHLD2 or SHLD2-C proteins-were unable to suppress RAD51 focus formation in BRCA1 KO 53BP1 KO cells when fused to the RNF8 FHA domain ( Fig. 4b and Extended Data Fig. 9a ). Expression of full-length SHLD2 m1 and SHLD2(S) in BRCA1 KO SHLD2 KO cells also failed to suppress RAD51 focus formation induced by ionizing radiation, unlike wildtype SHLD2 (Extended Data Fig. 10a, b ). Importantly, both mutants localized to DSB sites (Extended Data Fig. 10c, d ) and interacted with the other members of the shieldin complex (Extended Data Fig. 10e ). Therefore, the SHLD2 m1 and SHLD2(S) mutants are defective in suppressing homologous recombination.
Notably, the SHLD2-C m1 mutant was completely defective in ssDNA binding (Fig. 4d , lane 3) whereas the SHLD2(S)-C mutant displayed reduced and aberrant ssDNA-binding behaviour (Fig. 4d , lane 4). Because the m1 mutation produces a protein that is defective both in ssDNA-binding and suppression of homologous recombination, but which is proficient in both complex assembly and DSB recruitment, we conclude that ssDNA binding by shieldin is critical for 53BP1-dependent DSB repair.
In conclusion, the identification of shieldin forces us to re-evaluate how DNA end stability is regulated in vertebrates. Our results are consistent with a model in which shieldin is the ultimate mediator of 53BP1-dependent DNA repair by binding ssDNA and occluding access to resection nucleases ( Fig. 4f ). Our discovery of shieldin also has implications for the management of BRCA1-mutated malignancies, as alterations in shieldin-coding genes may cause clinical resistance to PARPi.
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MEthodS
Plasmids. DNA corresponding to sgRNAs was cloned into pX330 (Addgene: 42230, Cambridge), LentiGuide-Puro (Addgene: 52963), LentiCRISPRv2 (Addgene: 52961), or a modified form in which Cas9 was replaced by NLS-tagged GFP or mCherry using AgeI and BamHI (designated as LentiGuide-NLS-GFP or -mCherry), as described 29, 30 . Sequences of the sgRNAs used in this study are included in Supplementary Table 5 . Coding sequences of C20orf196 and the short isoform of FAM35A were obtained from the ORFeome collection (http://horfdb. dfci.harvard.edu/), archived in the Lunenfeld-Tanenbaum Research Institute's OpenFreezer 31 . The complete coding sequence of the long isoform of FAM35A was generated by combining a synthesized fragment (GeneArt, Regensburg) corresponding to the long isoform C terminus using an internal KpnI restriction site. The coding sequence of CTC534A2.2 was generated by gene synthesis (GeneArt). The coding sequences were PCR amplified using AscI and ApaI flanking primers and cloned into pcDNA5-FRT/TO-eGFP and pcDNA5-FRT/TO-Flag to obtain N-terminally tagged FAM35A, C20orf196 and CTC534A2.2. pGLUE-HA-Strep-FAM35A was generated by PCR amplification of the long isoform of FAM35A and cloning into pGLUE (Addgene: 15100) using AscI and NotI. To generate FAM35A fragments and mutants, standard protocols for primer-directed mutagenesis or self-ligation of truncated PCR-products were used. To generate pcDNA5-FRT/ TO-V5-CTC534A2.2, eGFP was replaced by a V5 tag in the cloning vector pcDNA5-FRT/TO-eGFP using KpnI and AscI restriction enzymes after which the coding sequence for CTC534A2.2 was PCR-amplified and inserted into pcDNA5-FRT/TO-V5-MCS using AscI and XhoI restriction enzymes.
To generate RNF8-FHA fusions, the N terminus of RNF8 (amino acids 1-160) was PCR amplified from pcDNA3-RNF8-FHA(1-160)-RNF168 with flanking AscI sites and inserted into pcDNA5-FRT/TO-eGFP-FAM35A. eGFP (FHA)fusions of FAM35A were introduced into pCW57.1 (Addgene: 41393) by Gateway cloning using the pDONR221 donor vector. FAM35A amino acid substitution mutations and deletions were introduced by site directed mutagenesis and deletion PCR, respectively.
The REV7 coding sequence was obtained from the ORFeome collection and was cloned into the pDEST-FRT/TO-eGFP vector using Gateway cloning and into the pcDNA5-FRT/TO-Flag vector by PCR amplification. The N-terminal 967 residues of RIF1 were amplified by PCR and cloned into the pDONR221 vector using Gateway technology. The fragment was then integrated into the pDEST-mCherry-LacR vector by Gateway cloning. Plasmids for the traffic light reporter system were obtained from Addgene (pCVL-TrafficLightReporter-Ef1a-Puro lentivirus: #31482; pCVL-SFFV-d14GFP-Ef1a-HA-NLS-Sce(opt)-T2A-TagBFP: #32627). Cell lines and gene editing. 293T and RPE1-hTERT cell lines were obtained from ATCC (Manassas), 293 Flp-In cells were obtained from Invitrogen (Carlsbad) and SUM149PT 32 cells were obtained from Asterand Bioscience (Detroit). U2OS ER-mCherry-LacIFokI-DD cells (U2OS-265, referred to in the text as U2OS-FokI) were a kind gift of R. Greenberg (University of Pennsylvania). All cell lines are routinely authenticated by STR-analysis and tested negative for mycoplasma. 293T, 293 Flp-In, U2OS and RPE1 cells were cultured in high glucose-and GlutaMAXsupplemented DMEM (Gibco, Thermo Fisher Scientific, Waltham) + 1% penicillin-streptomycin (Thermo Fisher Scientific) and 10% heat inactivated fetal calf serum (Wisent, St-Bruno) at 37 °C, 5% CO 2 . SUM149PT cells were cultured in Ham's F12 medium (Gibco) supplemented with 5% FCS, 10 mM HEPES, 1 µg/ml hydrocortisone (Sigma-Aldrich, St. Louis), and 5 µg/ml insulin (Sigma-Aldrich) at 37 °C, 5% CO 2 . Except for RPE1 clonogenic survival assays, which were performed at 3% O 2 , cells were kept under normoxia conditions. Transient transfections of DNA and siRNA were performed using Lipofectamine 2000 (Thermo Fisher Scientific), PEI (Sigma-Aldrich) or calcium phosphate and Lipofectamine RNAiMAX, respectively (Thermo Fisher Scientific). siRNA efficiency was analysed by qPCR and immunoblotting. Stable integration of Flag-C20orf196/FAM35A/ REV7 with the Flp-In system was achieved by co-transfection of the pcDNA5-FRT/ TO plasmid with the recombinase vector pOG44 (Thermo Fisher Scientific) and hygromycin selection for integration. Lentiviral particles were produced in 293T cells by co-transfection of the targeting vector with vectors expressing VSV-G, RRE and REV using calcium phosphate or PEI (Sigma-Aldrich). Viral transductions were performed in the presence of 4-8 µg/µL polybrene (Sigma-Aldrich) at an MOI <1, unless stated otherwise. Transduced RPE1 cells were selected by culturing in the presence of 15 µg/ml puromycin. For the BRCA1-deficient mouse cell experiments, all experiments were performed using virus produced with the LentiCRISPRv2 backbone (see Supplementary Table 5 ) and cells were infected using polybrene (8 µg/ml). The medium was refreshed after 12 h and transduced cells were selected with puromycin.
The generation of RPE1-hTERT TP53 −/− BRCA1 KO Cas9 cells has been described elsewhere 33 . REV7, 53BP1, FAM35A and C20orf196 gene knockouts were generated by electroporation of LentiGuide or LentiCRISPRv2 vectors using a Lonza Amaxa II Nucleofector (Basel) (for sgRNA sequences used see Supplementary Table 5 ; REV7 sgRNA1, FAM35A sgRNA2 and C20orf196 sgRNA1 were used for clonal knockout generation). Twenty-four hours after transfection, cells were selected for 24-48 h with 15 µg/ml puromycin, followed by single clone isolation. Triple knockout cell lines of TP53, BRCA1 and 53BP1 were created by mutating BRCA1 from the TP53 −/− 53BP1 KO double knockout cell line. Triple knockout cell lines of TP53, BRCA1 and REV7, FAM35A or C20orf196 were created by mutating REV7, FAM35A or C20orf196 in the TP53 −/− BRCA1 KO cells. Loss of protein(s) was verified by immunoblotting when antibodies were available. Gene mutations were further confirmed by PCR amplification and TIDE analysis 34 (for  primers used for genomic PCR, see Supplementary Table 6 , for genomic editing information, see Supplementary Table 2 ).
To generate SUM149PT 53BP1, PARP1 or C20orf196 knockout populations of cells, SUM149PT-doxCAS9 cells were treated with doxycycline for 24 h at 1 µg/ml before transfection with EditR crRNA (Dharmacon, Lafayette). Transfection of guides 53BP1_5_1, 53BP1_5_3, PARP1_5_2, PARP1_5_4, C20orf196_5-1, C20orf196_5-2, C20orf196_5-3 and C20orf196_5-5 (see Supplementary Table 5 ) was performed at a concentration of 20 nM (crRNA:tracrRNA) in the presence of doxycycline (1 µg/ml) using Lipofectamine RNAiMAX in 48-well plates (35,000 cells per well). The following day cells were split 1:3, fed 24 h later with medium supplemented with 50 nM talazoparib (without doxycycline) and kept in batch culture or further split to generate single cell colonies. Drug-containing medium was replenished every 3-4 days until PARP inhibitor resistant pools or clones were established. Clones were subsequently picked, expanded and validated by genomic PCR and sequence analysis (for primers used, see Supplementary Table 6 , for genomic editing information, see Supplementary Table 2 ). Four SUM149PT C20orf196 KO clones with mutations were chosen for further experimentation: clone A (C20orf196 5-1-C1), clone B (C20orf196 5-1-C2), clone C (C20orf196 5-3-C5) and clone D (C20orf196 5-5-C4).
To generate 53BP1 KO double mutant clones, SUM149PT C20orf196 clones A and D were infected with a lentivirus expressing an sgRNA targeting TP53BP1 or a non-targeting control sgRNA (for sequences, see Supplementary Table 5 ) in medium containing 1 µg/ml doxycycline. Forty-eight hours after infection, puromycin (1 µg/ml) was added to the medium. Selection was maintained for 3 d, until the uninfected control cells were killed. Pools of selection-resistant cells were seeded into 384-well plates for short term survival assays (see below) or subcloned to generate clonal lines.
Mouse embryonic stem cells with a selectable conditional Brca1 deletion (Rosa26 CreERT2/wt ;Brca1 SCo/Δ ) 35 were cultured on gelatin-coated plates in 60% buffalo red liver (BRL) cell-conditioned medium supplied with 10% fetal calf serum, 0.1 mM β-mercaptoethanol (Merck, Kenilworth) and 10 3 U/ml ESGRO LIF (Millipore, Burlington) under normal oxygen conditions (21% O 2 , 5% CO 2 , 37 °C).
The KB1P-G3 2D cell line was previously established from a Brca1 −/− p53 −/− mouse mammary tumour and cultured as described 14 . In brief, cells were cultured in DMEM/F-12 medium (Life Technologies, Carlsbad) in the presence of 10% FCS, penicillin-streptomycin (Gibco), 5 µg/ml insulin (Sigma-Aldrich), 5 ng/ml epidermal growth factor (Life Technologies) and 5 ng/ml cholera toxin (Gentaur, Kampenhout) under low oxygen conditions (3% O 2 , 5% CO 2 at 37 °C).
The KB1P4 3D tumour organoid line was previously established from a Brca1 −/− p53 −/− mouse mammary tumour and cultured as described 36 . Cells were seeded in Basement Membrane Extract Type 2 (BME, Trevigen, Gaithersburg) on 24-well suspension plates (Greiner Bio-One, Kremsmünster) and cultured in AdDMEM/F12 supplemented with 10 mM HEPES (Sigma-Aldrich), GlutaMAX (Invitrogen), penicillin-streptomycin (Gibco), B27 (Gibco), 125 µM N-acetyll-cysteine (Sigma-Aldrich), and 50 ng/ml murine epidermal growth factor (Invitrogen).
CH12F3-2 mutant clones were edited either through transient transfection with pX330 plasmid constructs expressing sgRNAs against Trp53bp1 (sgRNA: Trp53bp1_e6_834, see Supplementary Table 5 ), Fam35a, and Ctc534a2.2 or by lentiviral lentiCRISPR v2 transduction for C20orf196. Double knockout cell lines of Fam35a and Trp53bp1 or C20orf196 were generated by transient transfection of a pX330 plasmid expressing an sgRNA against Trp53bp1 or by lentiviral transduction with lentiCRISPRv2 with an sgRNA targeting C20orf196. Antibodies, siRNAs and drugs. An overview of all the antibodies used in this study, including dilution factors, can be found in Supplementary Table 7 . The following siRNAs from Dharmacon were used in this study (final siRNA concentration: 10 or 20nM): 53BP1: siRNA #2 (D-003548-02-0020); RIF1: siGENOME RIF1 siRNA (D-027983-02-0050); REV7: siGENOME MAD2L2 siRNA (M-003272-03-0010); C20orf196: SMARTpool: siGENOME C20orf196 siRNA (M-018767-00-0005); FAM35A: SMARTpool: siGENOME FAM35A siRNA (M-013761-01-0005); CTC534A2.2 (custom order): siRNA#1: 5′-GGACAAAACUCAAUCAAAU-3′, siRNA#2: 5′-CAGUAGAUCUAUUGGAGUU-3′, siRNA#3: 5′-CUGGAAGACAU UUGGACAA-3′, siRNA#4: 5′-GCAAGAUAGUUUAAAGGCA-3′ (used as a pool).
The following drugs were used in the course of this study: olaparib (SelleckChem, Houston, or Astra Zeneca, Cambridge), talazoparib (SelleckChem), cisplatin (Sigma-Aldrich), the ATM-inhibitor KU60019 (Sigma-Aldrich), and etoposide (Sigma-Aldrich). Concentration and duration of treatment are indicated in the corresponding figure legends. Olaparib resistance screens. Viral particles of the TKOv1 sgRNA library were produced as previously described 37 . This library contains 91,320 sgRNA sequences, with a modal number of six sgRNAs per gene. Cas9-expressing cells were infected with an MOI <0.3 and the coverage of sgRNA representation was maintained at >100× (SUM149PT) or >200× (RPE1) (per replicate, if applicable). Twentyfour hours after transduction, transduced cells were selected for 120 h with 10 µg/ml puromycin (RPE1) or 48 h with 3 µg/ml puromycin, followed by 72 h with 0.5 µg/ml puromycin (SUM149PT). Three days after transduction, the transduced cells were split into three technical replicates. Cells were passaged once every three days until nine days after infection, at which time olaparib (16 nM for RPE1 TP53 −/− BRCA1 KO , 2 µM for SUM149PT) was added to the cells. Olaparibcontaining medium was refreshed every 4 d. Cells were collected at 3, 9, 18 and 23 d post-infection (RPE1) or at 3, 9, 19 and 26 d post-infection (SUM149PT) for downstream processing as described 37 . In short, total genomic DNA was isolated from 2 × 10 7 (t3 sample) or 1 × 10 7 (later time points) cells using the QIAamp DNA Blood Maxi Kit (Qiagen, Germantown). DNA was precipitated with ethanol and sodium chloride and reconstituted in EB buffer (10 mM Tris-HCl pH 7.5). sgRNA sequences were PCR-amplified using primers harbouring Illumina TruSeq adapters with i5 and i7 barcodes, and the resulting libraries were sequenced on a Illumina NextSeq500 (San Diego) using parameters previously described 37 . Analysis was performed using model-based analysis of genome-wide CRISPR-Cas9 knockout (MAGeCK) version 0.5.3 38 , in conjunction with Python v3.5.1 on a Mac OS X El Capitan operating system. Non-treated samples collected at day 9 after transduction were compared to treated samples collected at day 23 (RPE1) or day 26 (SUM149PT). The positive score for each gene was calculated by using the 'run' function with the following arguments: mageck run -l /path/to/TKOv1_library/ -n 08-02-2017_141703-sample-label test,CTRL -t 1 -c 0-fastq /path/to/fastq1 /path/to/fastq2. Ionizing radiation dropout screen and TKOv2 library. The TKOv2 lentiviral CRISPR library was used for whole-genome CRISPR knockout screening. To design TKOv2, all possible 20-mer sequences upstream of NGG PAM sites were collected where the SpCas9 double-strand break would occur within a coding exon (defined by hg19/Gencode v19 'appris_principal, ' 'appris_candidate_longest, ' or 'appris_candidate' transcript). Guides with 40-75% GC content were retained and further filtered to exclude homopolymers of length ≥ 4, SNPs (dbSNP138), and relevant restriction sites, including BsmI (GAATCG) and BsmBI (CGTCTC). Candidate gRNA + PAM sequences were mapped to hg19 and sequences with predicted off-target sites in exons or introns, or sequences with more than two predicted off-target sites (with up to two mismatches) in any location, were discarded. Remaining guides were scored using a 'sequence score table' as previously described 40 . Four guides per gene were selected, with a bias towards high sequence scores and maximal coverage across exons (that is, moderate-scoring guides targeting different exons were preferred to high-scoring guides targeting the same exon). The final library contains 70,555 gRNA targeting 17,942 protein-coding genes, as well as 142 sequences targeting LacZ, luciferase, and eGFP. Oligonucleotide sequences were ordered from CustomArray (Bothell), PCR-amplified, and cloned into the pLCKO vector as previously described 37 .
RPE1-hTERT TP53 −/− Cas9-expressing cells were transduced with the lentiviral TKOv2 library (see below) at a low MOI (~0.35) and puromycin-containing medium was added the next day to select for transductants. Selection was continued until 72 h post-transduction, which was considered the initial time point, t0. To identify ionizing radiation sensitizers, the negative-selection screen was performed by subculturing at days 3 and 6 (t3 and t6), at which point the cultures were split into two populations. One was left untreated while the second was treated with 3 Gy of ionizing radiation using a Faxitron X-ray cabinet (Faxitron, Tucson) every 3 d after day 6. Cell pellets were frozen at day 18 for gDNA isolation. Screens were performed in technical duplicates and library coverage of ≥ 375 cells per sgRNA was maintained at every step. gDNA from cell pellets was isolated using the QIAamp Blood Maxi Kit (Qiagen) and genome-integrated sgRNA sequences were amplified by PCR using the KAPA HiFi HotStart ReadyMix (Kapa Biosystems, Wilmington). i5 and i7 multiplexing barcodes were added in a second round of PCR and final gel-purified products were sequenced on Illumina NextSeq500 systems to determine sgRNA representation in each sample. DrugZ 41 was used to identify gene knockouts which were depleted from ionizing radiation-treated t18 populations but not depleted from untreated cells. Two-colour competitive growth assay. Twenty thousand cells were infected at an MOI of ~1.2 to ensure 100% transduction efficiency with either virus particles of NLS-mCherry LacZ-sgRNA or NLS-GFP GOI-sgRNA. Ninety-six hours after transduction, mCherry-and GFP-expressing cells were mixed 1:1 (2,500 cells + 2,500 cells) and plated with or without olaparib (16 nM) or etoposide (100 nM) in 12-well format. During the course of the experiment, cells were subcultured when near-confluency was reached. Olaparib-or etoposide-containing medium was replaced every three days. Cells were imaged for GFP-and mCherry signal the day of initial plating (t = 0) and on days 3, 6, 9, 12, 15 and 18 (olaparib), or, in a separate set of experiments, on days 5, 10, 15 and 20 (etoposide). Cells were imaged using the automatic InCell Analyzer (GE Healthcare Life Sciences, Marlborough) with a 4× objective. Segmentation and counting of the number of GFP-positive and mCherry-positive cells was performed using an Acapella script (PerkinElmer, Waltham). Efficiency of indel formation was analysed by performing PCR amplification of the region surrounding the sgRNA sequence and TIDE analysis on DNA isolated from GFP-expressing cells 9 d post-transduction. Mass spectrometry. Following 24 h of doxycycline-induction of stably integrated 293 FLP-IN cells (expressing Flag, Flag-FAM35A, Flag-REV7, Flag-C20orf196, Flag-CTC-534A2.2), cell pellets from two 150-mm plates were lysed in 50 mM HEPES-KOH (pH8.0), 100 mM KCl, 2 mM EDTA, 0.1% NP-40, 10% glycerol and affinity-purified using Flag-M2 magnetic beads (Sigma-Aldrich). Subsequently, digestion with trypsin (Worthington, Columbus) was performed on-beads. All immunoprecipitations were performed in biological replicates (three for CTC-534A2.2, five for C20orf196 and six for FAM35A and REV7).
For liquid chromatography-tandem mass spectrometry analysis, peptides were reconstituted in 5% formic acid and loaded onto a 12-15-cm fused silica column with pulled tip packed with C18 reversed-phase material (Reprosil-Pur 120 C18-AQ, 3 µm, Dr. Maisch, Ammerbuch-Entringen). Peptides were analysed using an LTQ-Orbitrap Velos (Thermo Scientific) or a 6600 Triple TOF (AB SCIEX, Framingham) coupled to an Eksigent NanoLC-Ultra HPLC system and a nano-electrospray ion source (Proxeon Biosystems, Thermo Fisher Scientific). Peptides were eluted from the column using a 90-100-min gradient of acetonitrile in 0.1% formic acid. Tandem mass spectrometry spectra were acquired in a data-dependent mode for the top 10 most abundant ions using collisioninduced dissociation. After each run, the column was washed extensively to prevent carry-over.
Mass spectrometry data extraction and interaction scoring was performed essentially as described previously 42 . In short, raw mass spectrometry files were converted to mzXML and analysed using the iProphet pipeline 43 , implemented within ProHits 44 . The data were searched against the human and adenovirus complements of the Uniprot (forward and reverse) database (Version 2017_09; reviewed Swiss-Prot entries only), to which common epitope tags were added as well as common contaminants (common contaminants are from the Max Planck Institute, http://141.61.102.106:8080/share.cgi?ssid=0f2gfuB, and the Global Proteome Machine, http://www.thegpm.org/crap/index.html; 85,393 entries were searched). Mascot and Comet search engines were used with trypsin specificity (2 missed cleavages allowed) and deamidation (NQ) and methylation (M) as variable modifications. Charges +2, +3 and +4 were allowed with a parental mass tolerance of maximum 12 ppm and a fragment bin tolerance of 0.6 Da selected for Orbitrap instruments, while 35 ppm and 0.15 Da were allowed for the TripleTOF 6600. For subsequent SAINT analysis (see below), only proteins with an iProphet protein probability ≥ 0.95 were considered, corresponding to an estimated protein FDR of ~0.5%.
Interactions were analysed with SAINTexpress (v3.6.1) 45, 46 . SAINT probability scores were computed independently for each replicate against eight biological replicate analyses of the negative control (Flag alone; controls were 'compressed' to six virtual controls to increase robustness as described 47 ) and the average probability (AvgP) of the best three out of three (CTC534A2.2), five out of five (C20orf196) or six (FAM35A, REV7) biological replicates for each bait was reported as the final SAINT score. Preys with an estimated FDR ≤ 1% were considered true interactors (AvgP ≥ 0.91). The entire dataset, including the peptide identification and complete SAINTexpress output was deposited as a complete submission in ProteomeXchange through the partner MassIVE housed at the Center for Computational Mass Spectrometry at University of California, San Diego (UCSD; http://massive.ucsd.edu). Data are available at MassIVE (ftp://massive.ucsd.edu/ MSV000082207). Unique accession numbers are MSV000082207 and PXD009313, respectively. Data can also been viewed at the prohits website (prohits-web.lunenfeld.ca) under dataset 29: Durocher laboratory. Data in Fig. 1f is represented using Cytoscape, using analyses with an FDR ≤ 1 or 5%. Letter reSeArCH in sample buffer. Pull-downs and whole cell extracts were loaded onto SDS-PAGE gels, followed by immunoblotting and probing with indicated antibodies. For GFP-CTC534A2.2 immunoprecipitations, an identical GFP-Trap pulldown procedure as above was used. For V5-CTC534A2.2 immunoprecipitations, lysates from one confluent 10-cm dish of 293T cells transfected with 10 µg pcDNA5.1-FRT/TO-V5-CTC534A2.2 vector was incubated with 10 µg/ml anti-V5 antibody (Invitrogen) for 2 h at 4 °C. Subsequently, 50 µl of protein G Dynabeads (Invitrogen) was added to the lysates and incubated for an additional 1 h at 4 °C. Beads were washed 4 times with lysis buffer and boiled in 50 µl 2 × SDS buffer. Clonogenic survival assays. RPE1-hTERT TP53 −/− cells were seeded in 10-cm dishes (wild type, 250 cells; BRCA1 KO 53BP1 KO , 500 cells; BRCA1 KO or BRCA1 KO C20orf196 KO , 1,500 cells; BRCA1 KO FAM35A KO , 750 cells) in the presence of 800 nM cisplatin or 16 nM olaparib or left untreated. Cisplatin dosing lasted 24 h, after which cells were grown in drug-free medium. Olaparib-containing medium was refreshed after 7 d. After 14 d, colonies were stained with crystal violet solution (0.4% (w/v) crystal violet, 20% methanol) and manually counted. Relative survival was calculated for the drug treatments by setting the number of colonies in non-treated controls at 100%.
For Rosa26 CreERT2/wt Brca1 SCo/Δ cells, Cre-mediated inactivation of the endogenous mouse Brca1SCo allele was achieved by overnight incubation of cells with 0.5 µM 4-hydroxytamoxifen (Sigma-Aldrich). Four days after switching, cells were seeded in triplicate at 10,000 cells per well in 6-well plates for clonogenic survival assays. For experiments with Rosa26 CreERT2/wt Brca1 SCo/Δ p53-null cells, cells were plated in the presence of 15 nM olaparib. Cells were stained with 0.1% crystal violet one week later. Clonogenic survival assays with PARPi (olaparib) and ATMi (KU60019) combination treatment were performed as described previously with minor adjustments 42 . Five thousand KB1P-G3 cells were seeded per well into 6-well plates on day 0, and then PARPi, ATMi, both or neither were added. The medium was refreshed every 3 d. On day 6, the ATMi alone and untreated groups were stopped and stained with 0.1% crystal violet, the other groups were stopped and stained on day 9. Plates were scanned with a GelCount (Oxford Optronics, Abingdon). Quantifications were performed by solubilizing the retained crystal violet using 10% acetic acid and measuring the absorbance at 562 nm using a Tecan plate reader (Tecan, Männedorf). Short-term survival assays. Ten thousand RPE1-hTERT Cas9 TP53 −/− parental cells and additional mutants (BRCA1 KO and/or FAM35A KO ) with or without stable integration of indicated eGFP fusions by viral transduction were seeded in 12-well format with or without 200 nM olaparib (and 1 µg/ml doxycycline if applicable). Medium with olaparib (and doxycycline) was replaced after 4 d, and cells were trypsinized and counted after seven days using an automated Z2 Coulter Counter analyser (Beckman Coulter, Indianapolis).
SUM149PT cells were plated at 500 cells per well in 384-well plates and varying amounts of talazoparib in DMSO were added the following day using an Echo 550 liquid handler (Labcyte, San Jose). After 5 d of growth, cell survival was assayed using CellTiter-Glo according to the manufacturer's protocol (Promega, Madison). Immunofluorescence. For 53BP1 immunofluorescence, cells were cultured on coverslips and treated with 5 or 10 Gy X-ray irradiation and fixed with 2-4% paraformaldehyde (PFA) 1 h after irradiation. Cells were permeabilized with 0.3% Triton X-100, followed by blocking in 10% goat serum, 0.5% saponin, 0.5% NP-40 in PBS (blocking buffer A). Cells were co-stained using 53BP1 and γH2AX primary antibodies (see Supplementary Table 7 ) in blocking buffer A for 1.5 h at room temperature, followed by 4 washes in PBS, incubation with appropriate secondary antibodies in blocking buffer A plus 0.8 µg/mL DAPI for 1.5 h at room temperature, and finally four washes in PBS.
For RAD51 immunofluorescence, cells with or without stable integration of eGFP-tagged proteins or sgRNAs via viral transduction were grown on glass coverslips and treated with 10 Gy X-ray irradiation and recovered for 3 to 6 h (as indicated). Cells were fixated and extracted using 1% PFA, 0.5% Triton X-100 in PBS for 20 min at room temperature, followed by a second extraction/fixation using 1% PFA, 0.3% Triton X-100, 0.5% methanol in PBS for 20 min at room temperature. Blocking, primary and secondary antibody incubations (1.5 h at room temperature followed by 4 PBS washes) were performed in BTG buffer (10 mg/mL BSA, 0.5% Triton X-100, 3% goat serum, 1 mM EDTA in PBS) or PBS + (0.5% BSA, 0.15% glycine in PBS).
For REV7 and RIF1 immunofluorescence, cells were grown on glass coverslips, treated with 5 or 10 Gy X-ray irradiation and fixed with 2-4% PFA 1-2 h after irradiation. Cells were permeabilized with 0.3% Triton X-100. For REV7 blocking, primary and secondary antibody incubations (1.5 h at room temperature followed by 4 washes in PBS) were performed in blocking buffer A. For RIF1 blocking, primary and secondary antibody incubations (1.5 h at room temperature followed by 4 washes) were performed in PBG buffer (0.2% cold water fish gelatin (Sigma Aldrich), 0.5% BSA in PBS).
For GFP-shieldin focus and laser stripe analysis, U2OS or RPE1 cells were grown on glass coverslips and either transiently transfected with 1 µg vector expressing GFP-FAM35A or -CTC534A2.2, or virally transduced with GFP-FAM35A-expressing vector. Forty-eight hours after transfection, or 24 h after 0.5 µg/ml doxycyclin induction, cells were treated with 5 Gy X-ray irradiation or micro-irradiated, pre-extracted 10 min on ice with NuEx buffer (20 mM HEPES, pH 7.4, 20 mM NaCl, 5 mM MgCl2, 0.5% NP-40, 1 mM DTT and protease inhibitors) followed by 10 min 2% PFA fixation 1 h post-ionizing radiation or microirradiation. Antibody staining and blocking were performed as described above except in PBS + 0.1% Tween-20 + 5% BSA using GFP and γH2AX antibodies. DAPI (0.8 µg/ml) was included in all experiments to stain nuclear DNA. Coverslips were mounted using Prolong Gold mounting reagent (Invitrogen) or Aqua PolyMount (Polyscience, Warrington). Images were acquired using a Zeiss LSM780 laser-scanning microscope (Oberkochen), a Leica SP8 confocal microscope (Wetzlar) or a Zeiss AxioImager D2 widefield fluorescence microscope. Foci were manually counted.
RAD51 immunofluorescence in KB1P-G3 cells was performed as previously described, with minor modifications 10 . Cells were grown on 8-well chamber slides (Millipore). Ionizing-radiation induced foci were induced by gamma-irradiation (10 Gy) 4 h before sample preparation. Cells were then washed in PBS++ (2% BSA, 0.15% glycine, 0.1% Triton X-100) and fixed with 2% PFA/PBS++ for 20 min on ice. Fixed cells were washed with PBS++ and were permeabilized for 20 min in 0.2% Triton X-100/PBS++. All subsequent steps were performed in PBS++. Cells were washed thrice and blocked for 30 min at room temperature, incubated with the primary antibody for 2 h at room temperature, washed thrice and incubated with the secondary antibody for 1 h at room temperature. Lastly, cells were mounted and counterstained using Vectashield mounting medium with DAPI (H1500, Vector Laboratories, Burlingame).
Scale bars indicated in the figure panels represent 10 µm, unless stated otherwise. LacR-RIF1 N-terminus and FokI-induced focus formation. For monitoring recruitment of GFP-tagged shieldin subunits to mCherry-LacR-Rif1(1-967) foci, 150,000 U2OS-FokI cells (known also as U2OS-DSB) 48 were seeded on 6-well plates containing glass coverslips without any induction of FokI. Twenty-four hours after seeding, cells were transfected using 1µg of pDEST-mCherry-LacR or pDEST-mCherry-LacR-Rif1(1-967), if applicable, and 0.5-1 µg of GFP fusion expression vectors. Cells were fixed with 4% PFA 24-48 h after transfection. For monitoring the localization of the FAM35A N terminus to Rif1(1-967) foci with siRNA knockdown of other shieldin subunits, an essentially identical protocol was used with the following adjustments: 350,000 U2OS-FokI cells were reverse-transfected with Lipofectamine RNAiMAX-siRNA (10 nM) complex. Twenty-four hours after siRNA transfection, the mCherry-LacR and GFP fusion plasmids were transfected. Cells were fixed with 4% PFA 48 h after DNA transfection. For monitoring recruitment of GFP-tagged shieldin subunits to DSBs at the LacO array, FokI stabilization and nuclear translocation was induced by treating cells with 0.1 µM Shield1 (Clontech, Mountain View) and 10 µg/ml hydroxytamoxifen for 4 h. ImageJ (https://imagej.nih.gov/ij/) was used to quantify foci in the U2OS-FokI system. An mCherry focus and DAPI nuclear signal were used to generate masks. The average GFP fluorescence or immunofluorescence intensity in the mCherry focus mask was divided by the corresponding average nuclear intensity, and the ratio is reported. Cells displaying a ratio of focus/nuclear average intensity >3 are defined as containing a focus. Microirradiation. For laser microirradiation, virally transduced RPE1 cells expressing the indicated eGFP-tagged proteins were grown on glass coverslips and transfected with siRNAs. Forty-eight hours after transfection, protein expression was induced using 0.5 µg/ml doxycycline, and 24 h later cells were presensitized with 1 µg/ml Hoechst for 15 min at 37 °C. DNA damage was introduced with a 355-nm laser (Coherent, Santa Clara, 40mW) focused through a Plan-Apochromat 40× oil objective to yield a spot size of 0.5-1 mm using a LSM780 confocal microscope (Zeiss) and the following laser settings: 100% power, 1 iteration, frame size 128 × 128, line step 7, pixel dwell: 25.21 µs. Traffic light reporter assay. Cells were infected with pCVL.TrafficLightReporter. Ef1a.Puro lentivirus at a low MOI (0.3-0.5) and selected with puromycin (15 µg/µl). Cells (7 × 10 5 ) were nucleofected with 5 µg of pCVL.SFFV.d14GFP.Ef1a. HA.NLS.Sce(opt).T2A.TagBFP plasmid DNA in 100 µl of electroporation buffer (25 mM Na 2 HPO 4 pH 7.75, 2.5 mM KCl, 11 mM MgCl 2 ), using program T23 on a Nucleofector 2b (Lonza). After 72 h, GFP and mCherry fluorescence was assessed in BFP-positive cells using a Fortessa X-20 (BD Biosciences, San Jose) flow cytometer. Phospho-RPA immunoblotting. For phospho-RPA staining, CH12 cells were left untreated, or were treated with 25 Gy of ionizing radiation using a Faxitron X-ray cabinet, and were then collected by centrifugation 3 h later. Pellets were lysed on ice for 10 min in high salt lysis buffer (50 mM Tris-HCl pH 7.6, 300 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1 mM DTT, 1× EDTA-free protease inhibitor cocktail (Roche, Basel)), cleared by centrifugation at 20,000g for 10 min at 4 °C, and quantified by bicinchoninic acid assay (BCA; Pierce, Thermo Fisher Scientific). Equal amounts of whole-cell extracts were separated by SDS-PAGE on 4-12% Bis-Tris gradient gels (Invitrogen), transferred to nitrocellulose and immunoblotted for pRPA32 (S4/S8). Mouse mammary tumour models. All animal experiments were approved by the Animal Ethics Committee of The Netherlands Cancer Institute (Amsterdam) and performed in accordance with the Dutch Act on Animal Experimentation (November 2014). KB1P4 tumour organoids were transduced using spinoculation as previously described 49 . NMRI-nude female mice were purchased from Janvier Laboratories and used for transplantation studies at the age of 6-9 weeks. A power analysis was performed to calculate that a minimum of 8 mice per group were needed to achieve a power of 0.8 (two-sided test, alpha = 0.05).Tumour organoids were allografted in mice as previously described with minor adjustments 36 . In brief, tumour organoids were collected, incubated with TripLE at 37 °C for 5 min, dissociated into single cells, washed and embedded in a 1:1 mixture of tumour organoid culture medium and Basement Membrane Extract (Trevigen) in a cell concentration of 10 4 cells per 40 µl. Subsequently, 10 4 cells were injected in the fourth right mammary fat pad of NMRI nude mice. Mammary tumour size was determined by caliper measurements and tumour volume was calculated (0.5 × length × width 2 ). Treatment of tumour-bearing mice was initiated when tumours reached a size of 50-100 mm 3 . Mice were randomly allocated into the untreated (n = 8) or olaparib treatment group (n = 8). Olaparib was administered in a blinded fashion at 100 mg/kg intraperitoneally for 80 consecutive days. Animals were killed with CO 2 when the tumour reached a volume of 1,500 mm 3 . The tumour was collected, fixed in formalin for histology and several tumour pieces were collected for DNA analysis. Class switch recombination assays. To induce switching in CH12F3-2 murine B cell lymphoma cells, 2 × 10 5 cells were cultured in CH12 medium supplemented with a mixture of IL4 (10 ng/mL, R&D Systems #404-ML-050, Minneapolis), TGFβ (1 ng/ml, R&D Systems #7666-MB-005) and anti-CD40 antibody (1 µg/ml, #16-0401-86, eBioscience, Thermo Fisher) for 48 h. Cells were then stained with anti-IgA-PE and fluorescence signal was acquired on an LSR II or Fortessa X-20 flow cytometer (BD Biosciences). To probe AID levels in the stimulated cells, immunoblotting was performed on total cell lysates using anti-AID and anti-β-actin antibodies (Supplementary Table 7 ). Band quantification was analysed by ImageJ. Plasmid integration assay. Two hundred thousand RPE1 cells were seeded into 6-well plates and 24 h later transfected with 2 µg of BamHI/EcoRI-linearized peG-FP-c1 using PEI. Seventy-two hours after transfection, cells were seeded for colony formation into 10-cm dishes in the presence (50,000 cells per dish) or absence (500 cells per dish) of 600 µg/ml G418. At this point, transfection efficiency was analysed by measuring GFP-positivity using flow cytometry. Medium with G418 was refreshed every 3 d. Fourteen days after seeding, colonies were stained with crystal violet solution and manually counted. NHEJ efficiency was calculated according to the following formula: The data shown for the different knockout clones in Extended Data Fig. 8e represent NHEJ efficiency as calculated with the above formula, followed by normalization to wild-type cells (for which NHEJ efficiency is set to 100%). DNA binding assays. Shieldin proteins were isolated using the immunoprecipitation protocol described above with the following modifications. 293T cells were transfected with pGLUE-FAM35A(421-904), the indicated mutants of this construct, or the empty pGLUE Strep/HA-tagging vector and pcD-NA5.1-FRT/TO-Flag-C20orf196 in a 2:1 ratio for a total of 10 µg per 10 cm dish. Complexes were immunoprecipitated as described, except using a reduced NP-40 detergent concentration (0.1%) for the last two washes and elution buffer. Eluted proteins were concentrated using Amicon Ultra 0.5 ml 10K centrifugal filter units (Millipore). Concentrations of isolated proteins were estimated by SDS-PAGE and Coomassie staining, followed by comparison to a standard curve of known bovine serum albumin (BSA) concentrations measured by fluorescence in the 700-nM channel of the Odyssey imager (LI-COR). A radiolabelled ssDNA probe was prepared by T4 polynucleotide kinase (New England Biolabs, Ipswich) phosphorylation of HPLC-purified 59-nt DNA oligonucleotide (BioBasic, Markham); TACGTTAGTATGCGTTCTTCCTTCCAGAG GTTTTTTTTTTTTTTTTTTTTTTTTTTTTT) using [γ-32 P]ATP (3,000 Ci/mmol, 10 mCi/ml; Perkin-Elmer, Woodbridge). Unlabelled competitors were prepared using the same oligonucleotide sequence alone or hybri dized to the complementary s eq ue nce ( AAAAAAAAAAAAAAAAAAAAAAA AAAAAACCTCTGGAAGGAAGAACGCATACTAACGTA) by heating at 80 °C for 10 min and gradual cooling to room temperature overnight.
For electrophoretic mobility shift assays, 20 nM of labelled ssDNA probe was incubated with purified proteins for 20 min in the elution buffer with the addition of 1 mM DTT and 1 mg/ml BSA at room temperature. Glycerol was then added to a final concentration of 8.3% and resolved on 6% acrylamide-TAE gels. Gels were adhered onto blotting paper (VWR) and enclosed in plastic wrap. Gels were exposed to a storage phosphor screen (GE Healthcare) and visualized using a Typhoon FLA 9500 biomolecular imager (GE Healthcare). Dissociation constant (K d ) was determined in GraphPad Prism from nonlinear regression analysis assuming single-site specific binding of saturation titration experiments, defining all signal above the free probe band to be bound probe, as measured in ImageQuant TL(GE Healthcare). The fraction of probe bound is defined as: + Signal of bound probe Signal of bound probe signal of free probe and the concentration of unbound FAM35AC-C20orf196 (referred in the text as SHLD2-C-SHLD1) complex is calculated by multiplying the fraction of probe bound by the initial concentration of ssDNA probe, and subtracting this from the initial concentration of SHLD2-C-SHLD1, given the assumption of 1:1 binding. Statistical analysis. All data are represented as individual replicates and replicate number, mean and error bars are explained in the figure legends. The statistical tests we used (all of which were common tests) and resulting P values are indicated in the figure legends and/or figure panels and have been generated using GraphPad Prism software. Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this paper. Data availability. All source data represented in the graphs displayed in this article are available online ( Supplementary Data 1-12 ). Uncropped western blots can be found online as Supplementary Fig. 1 Table 3 ) are available at MassIVE (ftp://massive.ucsd. edu/MSV000082207, with unique accession numbers MSV000082207 and PXD009313). IP-MS data can also been viewed at the prohits website (http://prohits-web.lunenfeld.ca) under dataset 29: Durocher laboratory. Gene-editing efficiencies of the sgRNAs can be found in Supplementary  Table 2 . c, Representative flow cytometry plots of cells analysed with the traffic light reporter assay (data quantified in Fig. 2e, n ≥ 3) . d, Representative flow cytometry plots of cells analysed with the traffic light reporter assay (data quantified in b).
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Extended Data Fig. 4 | Shieldin localizes to DSB sites. a, Representative micrographs of the experiments quantified in Fig. 3c . b, Representative micrographs of the experiments quantified in Fig. 3e . c, Quantification of mRNAs for SHLD1, SHLD2 and SHLD3. RPE1 cells were transfected with siCTRL (non-targeting control siRNA) or siRNA targeting the indicated shieldin subunits. Forty-eight hours after transfection, mRNA was purified and reverse-transcribed before being assayed by quantitative real-time PCR. Data were normalized to the amount of GAPDH mRNA and expressed relative to the corresponding value for cells transfected with siCTRL. Data are presented as the mean ± s.d. (n = 3, independent siRNA transfections). d, Whole cell extracts from RPE1 wild-type cells transfected with the indicated siRNAs were processed for immunoblotting with the indicated antibodies. Tubulin is used as a loading control (n = 1 experiment; siRNA efficiency is also monitored by immunofluorescence). e, Quantification of 53BP1 and RIF1 recruitment to ionizing radiationinduced DSBs (1 h after irradiation with 10 Gy) following depletion of the indicated shieldin components. Data are represented as the mean ± s.d. Supplementary Table 2) or empty vector (EV). Data are represented as the mean ± s.d. (for BRCA1 KO 53BP1 KO , n = 4 biologically independent immunofluorescence experiments; for BRCA1 KO and BRCA1 KO SHLD2 KO , n = 6 biologically independent immunofluorescence experiments). P values were calculated using a two-tailed unpaired t-test. Left, BRCA1 KO EV versus sg53BP1-1 P = 0.0002; EV versus sgSHLD1-1 P = 0.0043; EV versus sgSHLD2-2 P = 0.0348; EV versus sgSHLD3-1 P = 0.0180; EV versus sgREV7-1 P = 0.0012). Middle, right: all comparisons to the EV condition were non-significant (NS). Values for BRCA1 KO 53BP1 KO EV versus sg53BP1-1 P = 0.2332; EV versus sgSHLD1-1 P = 0.4451; EV versus sgSHLD2-2 P = 0.9632; EV versus sgSHLD3-1 P = 0.1187; EV versus sgREV7-1 P = 0.0568. Values for BRCA1 KO SHLD2 KO : EV versus sg53BP1-1 P = 0.0550; EV versus sgSHLD1-1 P = 0.1864; EV versus sgSHLD2-2 P = 0.3568; EV versus sgSHLD3-1 P = 0.4641; EV versus sgREV7-1 P = 0.2888. b, Talazoparib sensitivity of wild type or two independent SHLD1 KO SUM149PT-dox-Cas9 clones (A and D) virally transduced with an sgRNA targeting 53BP1 (sg53BP1) or a control non-targeting sgRNA (sgCtrl), following induction of Cas9. Data are presented as the mean ± s.d. (n = 3 biologically independent experiments).
Extended Data Fig. 7 | Mapping the architecture of the shieldin complex. a, Streptavidin pulldown analysis determining which region of SHLD2 associates with the other shieldin subunits. WCEs of 293T cells transfected with an expression vectors for Flag-SHLD1, V5-SHLD3, GFP-REV7 and Strep/HA-tagged SHLD2, SHLD2-N (residues 2-420), SHLD2-C (residues 421-904) or empty Strep/HA vector (EV) were incubated with streptavidin resin and bound proteins were eluted with biotin. WCEs and elutions were analysed by SDS-PAGE and immunoblotting with the indicated antibodies. Tubulin was used as a loading control. Results are representative set of immunoblots from two independent experiments. Asterisk denotes a non-specific band. b, Mapping the SHLD3 and REV7 binding sites on the SHLD2 N terminus through streptavidin pulldowns with different SHLD2 constructs (detailed in Extended Data Fig. 6a ) and immunoblotting. Results are a representative of a set of immunoblots from three independent experiments. c, Affinity purification of shieldin complex components using N-terminally truncated SHLD2 (Δ1-50) analysed by immunoblotting (representative of three independent experiments). d, Streptavidin pulldown analysis of SHLD2 association with REV7 and SHLD3. 293T cells were transfected with siRNAs and expression vectors for epitope-tagged shieldin components as indicated (EV, empty Strep/HA vector). WCEs were incubated with streptavidin resin and bound proteins were eluted with biotin. WCEs and elutions were analysed by SDS-PAGE and immunoblotted with the indicated antibodies. Short and long exposures are shown for GFP and V5 immunoblots (n = 1). e, Dependency of V5-SHLD3 co-immunoprecipitation with GFP-REV7. 293T cells were transfected with siRNAs and expression vectors for epitope-tagged REV7 and SHLD3 as indicated (EV, empty V5 vector). WCEs were incubated with anti-V5 antibody and protein G resin. Bound proteins were boiled in SDS sample buffer and analysed by immunoblotting with GFP and V5 antibodies (n = 1). f, Association between SHLD3 and RIF1. WCEs of 293T cells transfected with an expression vector for unfused GFP (−) or GFP-SHLD3 (SHLD3) were incubated with GFP-Trap resin. Bound proteins were boiled in SDS sample buffer and analysed by SDS-PAGE and immunoblotting against 53BP1 and RIF1. Results are representative of 2 SHLD3 immunoprecipitations, using SHLD3 fused to GFP (shown here) and V5 (shown in Fig. 3g ) affinity tags.
Extended Data Fig. 9 | The role of DSB-targeted SHLD2 in the suppression of homologous recombination and the mapping of the SHLD2-C-SHLD1 complex binding to ssDNA. a, Representative micrographs of RPE1 BRCA1 KO 53BP1 KO cells transduced with the indicated GFP-fusion proteins, pre-extracted, fixed and stained for RAD51 and GFP 3 h after ionizing radiation (10 Gy). Protein expression was induced for 24 h before exposure to ionizing radiation using 1 µg ml −1 doxycycline. Data relates to Fig. 4b . Note that owing to the pre-extraction required for visualization of RAD51 foci, the visualization of non-FHAtagged SHLD2 is lost. b, SDS-PAGE analysis of purified SHLD2-C-SHLD1 complexes. Strep/HA-SHLD2(421-904)-Flag-SHLD1 complexes were purified from transiently transfected 293T cells. Concentrations of purified proteins were estimated by Coomassie staining and comparison to a standard curve of known BSA concentrations visualized by fluorescence at 700 nm. SHLD2-C m1 and SHLD2(S)-C denote SHLD2-C constructs carrying the OB-fold m1 mutation and the internal deletion (Δ655-723) corresponding to the naturally occurring splice variant of SHLD2, respectively. Open and filled arrowheads mark the bands corresponding to SHLD2-C and SHLD1, respectively. EV refers to empty Strep/HA vector. A representative stained gel from two independent experiments is shown. c, Representative image of the 32 P-labelled ssDNA EMSA with SHLD2-C-SHLD1 for K d determination shown in Fig. 4e. d , Model of the SHLD2 OBfold domains and the engineered mutations (red spheres, point mutations; red ribbons, splice variant deletion). Model relates to Fig. 4b, d .
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